Enopace Biomedical

Company Overview

Snapshot

Founded in October 2007 by Yossi Gross, Enopace Biomedical operates with 11–50 employees. The company has raised $25M across 3 funding rounds from 1 investor. In February 2013, the company secured a B Round of funding.

Business overview

Enopace Biomedical is a Health Tech & Life Sciences company focused on developing a minimally invasive neurostimulation device to treat heart failure patients. Its core technology, the Harmony™ System, is an implantable device designed to enhance cardiac efficiency by reducing left-ventricular workload through precise and personalized aortic stimulation. The system, which includes a wearable unit for therapy control, can be implanted in a standard catheterization procedure without general anesthesia. The company operates within the Medical Devices sector, specifically targeting Medical Treatment & Therapeutics, and serves healthcare providers in the cardiology field.

Strategic signal

In November 2015, Enopace Biomedical announced the world's first implantation of its endovascular neuromodulation device in a human for the treatment of congestive heart failure. This milestone demonstrated the clinical viability and potential of its Harmony™ System, signaling a significant advancement in minimally invasive treatments for heart failure and validating the company's innovative approach to neuromodulation in cardiology.

Company Intelligence Q&A

What is the primary focus of Enopace Biomedical?

Enopace Biomedical focuses on developing a minimally invasive neurostimulation device for patients suffering from heart failure.

When was Enopace Biomedical founded?

Enopace Biomedical was founded in October 2007.

What is the Harmony™ System?

The Harmony™ System is Enopace Biomedical's minimally invasive, implantable neurostimulation device designed to increase cardiac efficiency by reducing left-ventricular workload in heart failure patients.

What was a significant clinical milestone for Enopace Biomedical?

In November 2015, Enopace Biomedical announced the world's first implantation of its endovascular neuromodulation device in a human for the treatment of congestive heart failure.

What was the latest funding round for Enopace Biomedical?

Enopace Biomedical secured a B Round of funding in February 2013, with Sorin participating as an investor.